Alan Roemer

Board of Directors | Multiple Biotechnology Companies

Alan S. Roemer, MBA, MPH is a life sciences entrepreneur and board member who has launched three multi-billion-dollar biotechnology companies resulting in 9 new drug approvals, raised approximately $2 billion in private and public capital, consummated five IPOs, and executed numerous business development transactions. He currently serves as Chairman of the Board of Directors of IN8bio (Nasdaq:INAB); a Trustee and Treasurer of the Helene Fuld College of Nursing; a Strategic Partner of Forty51 Ventures; and a Senior Advisor of Biolojic Design. He previously served as a Chairman of the Board of UTILITY Therapeutics; a Director and Chair of the Audit, Compensation and Finance Committees of bit.bio; a Director and Audit Committee Chair of NexImmune (Nasdaq:NEXI); a Director of Envisagenics; and a Director of SomPharmaceuticals (acquired by Amryt Pharma (Nasdaq:AMYT)). Mr. Roemer received a BSBA from Georgetown University and MBA and MPH degrees from Emory University's Goizueta Business School and Rollins School of Public Health.